Mirla Avila, MD, discusses factors that guide initial disease-modifying therapy selection in MS, including disease activity, MRI findings, patient characteristics, and treatment preferences.
Transcript
Nowadays, it’s good that we have a lot of treatment options, but it’s important for us to choose the best one for the patient. This varies a lot depending on the patient’s age and ethnicity, because we know that Hispanic and Black patients can have more aggressive MS.
We also consider what the MRI looked like when we diagnosed MS. If there are a lot of enhancing lesions and a lot of activity, we’re definitely going to choose one of the higher-efficacy medications. We also consider the patient’s preferences. If they’re young and planning to start a family soon, we may choose a different medication based on the risks of pregnancy while taking it.
Again, male patients tend to have more aggressive disease than female patients, so there are many things we have to take into account. Personally, I like to sit down with the patient, talk about the options, and explain why I would choose one medication over another. In the end, the decision involves not only the physician but also the patient. I feel the patient needs to be involved in that decision.